Clinical trials: Bone Tumors
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia
The purpose of this study is to determine the ability of G-CSF to disrupt the bone marrow microenvironment as a means to increase the efficacy of chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia…
- Trial name
- NCT01331590
- Testing
- G-CSF, Ifosfamide, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer Metastatic, Bone Metastases
Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223
Radium-223 is the 5th treatment for metastasized castration resistant prostate cancer with a proven overall survival benefit. The improved survival of Radium-223 over placebo was demonstrated in the ALSYMPCA trial, which included…
- Trial name
- ROTOR (NCT03223597)
- Testing
- Radium-223 dichloride
- Where
- 20 sites in Netherlands
- Volunteers
- 300 people
- Sponsor
- The Netherlands Cancer Institute
Osteosarcoma, Ewing Sarcoma
Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma
Osteosarcoma and Ewing sarcoma treatment has not changed in the last 30 years. For other types of cancer the epidemiologic and prognostic correlations between dietary behavior, lifestyle and metabolic alterations (i.e.obesity…
- Trial name
- Metabol-Sarc (NCT04735289)
- Testing
- EPIC-COS Food Frequency Questionnaire diet Evaluation, Metabolome, Microbiota, Lymphocytes subpopulations
- Where
- 7 sites in Italy
- Volunteers
- 810 people, healthy volunteers welcome
- Sponsor
- Istituto Ortopedico Rizzoli
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients
Primary Objective: 1. To evaluate whether 5 azacytidine (5-aza)/valproic acid (VPA) or low dose ara-C produces longer event free survival time in patients age > or = 60 years with untreated Acute Myeloid Leukemia (AML) or high…
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
- Trial name
- NCT00382590
- Testing
- 5-Azacytidine, Ara-C, Valproic Acid (VPA)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
This phase I trial studies the side effects and best dose of anti-cluster of differentiation (CD)47 monoclonal antibody Hu5F9-G4 in treating patients with haematological malignancies including acute myeloid leukemia that has…
- Trial name
- NCT02678338
- Testing
- Hu5F9-G4
- Where
- 5 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Breast Cancer
A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)
The purpose of this study is to test MK0822 on reducing the risk of bone metastasis in women with breast cancer.
- Trial name
- NCT00692458
- Testing
- Comparator: odanacatib
- Sponsor
- Merck Sharp & Dohme LLC
Bone Marrow Transplant Complications, Hematologic Malignancy
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
The goal of this study is to evaluate whether a psychological intervention (BMT-CARE) is effective at improving the quality of life in caregivers and patients treated with hematopoietic cell transplant compared to usual care, and…
- Trial name
- BMT-CARE (NCT06472089)
- Testing
- BMT-CARE, Usual Care
- Where
- 3 sites in United States
- Volunteers
- 800 people
- Sponsor
- Massachusetts General Hospital
Myelodysplastic Syndrome
Erlotinib Study for Myelodysplastic Syndrome (MDS)
The purpose of this research study is to find out what effects, good and/or bad, erlotinib has on the patient and their myelodysplastic syndrome.
- Trial name
- NCT00977548
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Myelodysplastic Syndromes, Myeloid Leukemia
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
This study proposes a safe dosing regimen IFN-γ that is sufficient to stimulate IFN-γ receptors on malignant blasts in patients who developed relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after alloSCT…
- Conditions
- Myelodysplastic Syndromes, Myeloid Leukemia, Allogeneic Stem Cell Transplantation
- Trial name
- NCT04628338
- Testing
- IFN-γ (interferon gamma-1b) injection
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sawa Ito, MD
Multiple Myeloma
Diagnostic Imaging of Myeloma Bone Lesions
The purpose of this study is to compare the current standard whole-body x-ray with the advanced imaging techniques FDG-PET-CT, NaF-PET-CT and whole-body MRI in the detection of myeloma bone lesions.
- Trial name
- RAMP (NCT03147326)
- Testing
- FDG-PET-CT, NaF-PET-CT, Whole-body MRI
- Where
- Denmark
- Volunteers
- 14 people
- Sponsor
- Herlev Hospital
Solid Tumor Malignancy
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR…
- Trial name
- NCT03822117
- Testing
- Pemigatinib
- Where
- 90 sites in United States, Denmark and 9 more
- Volunteers
- 111 people
- Sponsor
- Incyte Corporation
Prostate Cancer
Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
This clinical trial is being conducted to recommend a safe and tolerable phase 2 dose of docetaxel or cabazitaxel when combined with clarithromycin in men who have developed castrate-resistant prostate cancer.
- Trial name
- NCT03043989
- Testing
- Docetaxel, Cabazitaxel, Clarithromycin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Overal Survival, Non-small Cell Lung Cancer
Bone Metastasis on the Survival of Gefitinib Effective Patients
Gefitinib is a selective small molecule epidermal growth factor receptors (EGFR) tyrosine kinase inhibitors (EGFR-TKI), it's curative effect on non-small cell lung cancer (NSCLC) has been confirmed by a number of prospective…
- Trial name
- NCT03157310
- Testing
- Gefitinib
- Volunteers
- 265 people
- Sponsor
- Qilu Hospital of Shandong University
Myeloproliferative Neoplasms
Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders
Myeloproliferative neoplasms (MPN) are clonal hematopoietic disorders sharing a common natural evolution: a chronic phase, characterized by a major risk of vascular events, followed by an accelerated phase eventually leading to…
- Trial name
- CTIM3 (NCT02823210)
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
This is a phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)
- Trial name
- NCT06680752
- Testing
- ARD103, Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- ARCE Therapeutics, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
This is a non-randomised, open-label phase I study of an investigational medicinal product (IMP) consisting of a HLA-A*02:01 restricted HA-1H T cell receptor transduced T cell (MDG1021) immunotherapy for relapsed or persistent…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
- Trial name
- NCT04464889
- Testing
- MDG1021 dose 1, MDG1021 dose 2, MDG1021 dose 3
- Where
- Netherlands
- Sponsor
- Medigene AG
Breast Neoplasms
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
The primary purpose of this study is to evaluate the tolerability and safety of E7090 as monotherapy and in combination with other anticancer agents in participants with ER+, HER2- recurrent/metastatic breast cancer and to…
- Trial name
- NCT04572295
- Testing
- E7090, Fulvestrant, Exemestane
- Where
- 11 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Eisai Co., Ltd.
Sarcoma, Soft Tissue Sarcoma
Gemcitabine Plus Ascorbate for Sarcoma in Adults
This study will enroll patients who have a diagnosis of locally advanced, unresectable or metastatic soft tissue or bone sarcoma (except gastrointestinal stromal tumors and Kaposi's sarcoma) from any site.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor
- Trial name
- NCT03468075
- Testing
- Ascorbate, Gemcitabine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mohammed Milhem, MBBS
Giant Cell Tumor of Bone
Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China
This prospective observational study is going to figure out the safety and efficacy of denosumab as an post-operative strategy.All the patients enrolled will take denosumab according to the protocols.We focus on the recurrence…
- Trial name
- NCT03358212
- Testing
- Denosumab
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well tazemetostat works in treating patients with brain tumors, solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have come back (relapsed) or do not respond to…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma
- Trial name
- NCT03213665
- Testing
- Tazemetostat
- Where
- 117 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)